IBB · iShares Biotechnology ETF ETF
iShares Trust
$211.92
-0.88%
At close · Sep 4
Net assets $9,087,528,995
Holdings252
1 month
+7.19%
Year to date
+25.68%
52-week range
$138.79–$217.12
30-session avg volume
1,509,278
Market performance
Adjusted close · up to five years
Fund profile
- Structure
- Open-end / ETF
- SEC series
- S000004350
- Report date
- Jun 30, 2026
- Holdings coverage
- Full reported portfolio
Portfolio concentration
Top 10 holdings54.33%
Calculated only when the SEC filing is stored with complete portfolio coverage.
Asset allocation
EC99.88%
STIV12.04%
DE0.00%
Country allocation
US96.35%
NL4.25%
DK2.40%
CH2.17%
BM1.43%
CA1.16%
KY0.87%
Other3.29%
Portfolio holdings
Latest linked SEC Form NPORT-P report.
| Holding | Ticker / CUSIP | Value | Weight |
|---|---|---|---|
| BlackRock Funds III | 066922519 | $1,059,724,091 | 11.66% |
| Vertex Pharmaceuticals, Inc. | VRTX | $734,315,959 | 8.08% |
| Amgen, Inc. | AMGN | $711,361,202 | 7.83% |
| Gilead Sciences, Inc. | GILD | $621,785,595 | 6.84% |
| Regeneron Pharmaceuticals, Inc. | REGN | $445,868,512 | 4.91% |
| Argenx SE | ARGX | $341,583,575 | 3.76% |
| Alnylam Pharmaceuticals, Inc. | ALNY | $283,622,639 | 3.12% |
| Natera, Inc. | NTRA | $262,677,550 | 2.89% |
| Revolution Medicines, Inc. | RVMD | $252,662,819 | 2.78% |
| Biogen, Inc. | BIIB | $224,089,654 | 2.47% |
| Illumina, Inc. | ILMN | $188,025,217 | 2.07% |
| Moderna, Inc. | MRNA | $180,306,731 | 1.98% |
| Insmed, Inc. | INSM | $162,203,032 | 1.78% |
| BeOne Medicines Ltd. | ONC | $160,774,375 | 1.77% |
| Incyte Corp. | INCY | $159,002,023 | 1.75% |
| United Therapeutics Corp. | UTHR | $157,564,164 | 1.73% |
| Roivant Sciences Ltd. | $129,587,174 | 1.43% | |
| Neurocrine Biosciences, Inc. | NBIX | $117,983,095 | 1.30% |
| Ascendis Pharma A/S | $116,859,367 | 1.29% | |
| Genmab A/S | GMAB | $101,669,080 | 1.12% |
| Exelixis, Inc. | EXEL | $93,913,564 | 1.03% |
| Ionis Pharmaceuticals, Inc. | IONS | $91,064,248 | 1.00% |
| Bridgebio Pharma, Inc. | BBIO | $89,231,658 | 0.98% |
| Medpace Holdings, Inc. | MEDP | $86,345,413 | 0.95% |
| Madrigal Pharmaceuticals, Inc. | MDGL | $82,548,545 | 0.91% |
| Bio-Techne Corp. | TECH | $78,097,994 | 0.86% |
| BioMarin Pharmaceutical, Inc. | BMRN | $77,168,208 | 0.85% |
| Charles River Laboratories International, Inc. | CRL | $76,488,783 | 0.84% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | $76,431,845 | 0.84% |
| Axsome Therapeutics, Inc. | AXSM | $74,691,076 | 0.82% |
| Cytokinetics, Inc. | CYTK | $71,932,817 | 0.79% |
| Krystal Biotech, Inc. | KRYS | $67,753,583 | 0.75% |
| Halozyme Therapeutics, Inc. | HALO | $65,110,856 | 0.72% |
| Praxis Precision Medicines, Inc. | PRAX | $61,940,167 | 0.68% |
| Abivax SA | ABVX | $61,142,886 | 0.67% |
| Alkermes plc | $60,513,396 | 0.67% | |
| BioNTech SE | BNTX | $60,215,726 | 0.66% |
| Vaxcyte, Inc. | PCVX | $58,157,263 | 0.64% |
| Kymera Therapeutics, Inc. | KYMR | $57,802,166 | 0.64% |
| Apogee Therapeutics, Inc. | 03770N101 | $53,579,783 | 0.59% |
| Protagonist Therapeutics, Inc. | PTGX | $52,998,198 | 0.58% |
| Rhythm Pharmaceuticals, Inc. | RYTM | $52,218,519 | 0.57% |
| Repligen Corp. | RGEN | $51,595,741 | 0.57% |
| Spyre Therapeutics, Inc. | SYRE | $48,623,386 | 0.54% |
| Bruker Corp. | BRKR | $47,394,097 | 0.52% |
| PTC Therapeutics, Inc. | PTCT | $46,321,237 | 0.51% |
| Nuvalent, Inc. | 670703107 | $45,699,323 | 0.50% |
| Twist Bioscience Corp. | TWST | $43,449,722 | 0.48% |
| Tempus AI, Inc. | TEM | $43,369,179 | 0.48% |
| Mirum Pharmaceuticals, Inc. | MIRM | $41,143,549 | 0.45% |